#United States #New York #Lucid Diagnostics #Esophageal Cancer #PAVmed

Lucid Diagnostics Joins Russell Indexes

Lucid Diagnostics Inc. (Nasdaq: LUCD), a prominent player in the field of cancer prevention through innovative medical diagnostics, has confirmed its upcoming inclusion in both the Russell 2000® Index and the more comprehensive Russell 3000® Index. This announcement, made on May 27, 2025, indicates that after U.S. equity markets close on June 27, 2025, Lucid will be formally recognized as part of these significant financial benchmarks.

Lucid’s ascent into these indices marks an important milestone for the company, which specializes in early detection tests aimed at preventing esophageal cancer, particularly for patients suffering from gastroesophageal reflux disease (GERD). Dennis McGrath, the Chief Financial Officer at Lucid, expressed gratitude for this opportunity, emphasizing that inclusion in such respected indices not only serves as validation of their past year's progress in enhancing shareholder value but is also expected to broaden their visibility amongst institutional investors.

The Russell 3000 Index, which encompasses the largest 3,000 publicly traded companies in the United States by market capitalization, provides a comprehensive overview of the U.S. stock market. The Russell 2000 Index focuses specifically on small-cap stocks, making Lucid's entry a noteworthy achievement for a company of its size. This annual re-evaluation and reconstitution of the Russell indices, which occurs every April, ensures that companies are ranked according to their total market capitalization, validating Lucid’s growth as they move into this new chapter.

Investors looking closely at index-linked financial products can benefit from this significant development as approximately $10.6 trillion in assets are currently benchmarked against Russell indices. This includes numerous index funds that guide institutional and retail investors alike in their investment strategies.

Lucid Diagnostics, as a subsidiary of PAVmed Inc. (Nasdaq: PAVM), has been committed to revolutionizing cancer prevention through innovative testing tools. Their flagship product, the EsoGuard® Esophageal DNA Test, represents the first commercially available method to detect esophageal precancer cells noninvasively. Using the EsoCheck® Esophageal Cell Collection Device, the test is designed to identify conditions that could lead to cancer at an early stage, providing patients with crucial information for preventative care.

In the realm of cancer diagnostics, Lucid is addressing a vital public health concern. With millions of patients suffering from GERD, their work focuses on identifying individuals at risk for developing esophageal precancer and cancer. By making these innovative detection tools widely available, Lucid is not just improving patient outcomes, but it is also changing the landscape of preventative healthcare.

Furthermore, the importance of joining the Russell indices is clearer considering the prevailing economic landscape, where investor focus tends to drift towards companies that showcase growth potential and sound economic health. By being part of these indices, Lucid Diagnostics can enhance its credibility and attract more investment—key factors in propelling its ongoing research and development.

As Lucid prepares for this important transition, it continues to monitor all variables that could impact its performance. From market fluctuations to the ongoing ramifications of the COVID-19 pandemic, maintaining transparency with investors is paramount. Lucid's management understands that navigating these complexities will require effort and responsiveness to both existing and emerging challenges.

For more details about Lucid Diagnostics and its cancer detection innovations, interested parties can explore its official website at www.luciddx.com or learn more about its parent organization PAVmed at www.pavmed.com.

Their dedication to cancer prevention is summarized by their pioneering strategy—to prioritize early detection and reduce the incidence of cancer deaths through innovative medical solutions. As they embark on their journey within the Russel indices, Lucid Diagnostics stands at the forefront of transforming cancer care, driven by a commitment to affordable and accessible healthcare solutions.